{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:26:10Z","timestamp":1787772370920,"version":"build-2784847793"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T00:00:00Z","timestamp":1698364800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007452","name":"Wu Jieping Medical Foundation","doi-asserted-by":"publisher","award":["320.6750.2022-19-58"],"award-info":[{"award-number":["320.6750.2022-19-58"]}],"id":[{"id":"10.13039\/100007452","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81960517"],"award-info":[{"award-number":["81960517"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81960542"],"award-info":[{"award-number":["81960542"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82360614"],"award-info":[{"award-number":["82360614"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["surgopensci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgery Open Science"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.sopen.2023.10.008","type":"journal-article","created":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T22:20:02Z","timestamp":1698790802000},"page":"171-183","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Efficacy and safety of utidelone plus capecitabine in advanced first-line therapy for metastatic breast cancer: A multicenter real-world study"],"prefix":"10.1016","volume":"16","author":[{"given":"Pingping","family":"Bi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuqin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanrong","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoyan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueqiong","family":"Xun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoqiang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shicong","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.sopen.2023.10.008_bb0005","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"7586","key":"10.1016\/j.sopen.2023.10.008_bb0010","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/nature16863","article-title":"Cancer: bet on drug resistance","volume":"529","author":"Settleman","year":"2016","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.sopen.2023.10.008_bb0015","doi-asserted-by":"crossref","first-page":"523","DOI":"10.4143\/crt.2022.1360","article-title":"A phase II trial of S-1 and oxaliplatin in patients with metastatic breast cancer previously treated with anthracycline and taxane (KCSG-BR07-03)","volume":"55","author":"Lee","year":"2023","journal-title":"Cancer Res Treat"},{"issue":"12","key":"10.1016\/j.sopen.2023.10.008_bb0020","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","article-title":"5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)","volume":"31","author":"Cardoso","year":"2020","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.sopen.2023.10.008_bb0025","doi-asserted-by":"crossref","first-page":"691","DOI":"10.6004\/jnccn.2022.0030","article-title":"Breast cancer, version 3.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Gradishar","year":"2022","journal-title":"J Natl Compr Cancer Netw"},{"issue":"6","key":"10.1016\/j.sopen.2023.10.008_bb0030","doi-asserted-by":"crossref","first-page":"769","DOI":"10.20892\/j.issn.2095-3941.2022.0277","article-title":"Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) guidelines in 2022: stratification and classification","volume":"19","author":"Li","year":"2022","journal-title":"Cancer Biol Med"},{"issue":"34","key":"10.1016\/j.sopen.2023.10.008_bb0035","doi-asserted-by":"crossref","first-page":"3840","DOI":"10.1200\/JCO.2014.55.2984","article-title":"Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer","volume":"32","author":"O\u2019Shaughnessy","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.sopen.2023.10.008_bb0040","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejca.2019.02.002","article-title":"Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: a randomised clinical trial","volume":"112","author":"Yuan","year":"2019","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.sopen.2023.10.008_bb0045","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.clbc.2018.07.024","article-title":"Efficacy and safety of ixabepilone and capecitabine in patients with advanced triple-negative breast cancer: a pooled analysis from two large phase III, randomized clinical trials","volume":"18","author":"Rugo","year":"2018","journal-title":"Clin Breast Cancer"},{"issue":"5","key":"10.1016\/j.sopen.2023.10.008_bb0050","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.4103\/jcrt.JCRT_792_19","article-title":"A randomized controlled phase II trial of vinorelbine plus capecitabine versus docetaxel plus capecitabine in anthracycline-pretreated women with metastatic breast cancer","volume":"16","author":"Li","year":"2020","journal-title":"J Cancer Res Ther"},{"issue":"4","key":"10.1016\/j.sopen.2023.10.008_bb0055","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S1470-2045(15)70064-1","article-title":"Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial","volume":"16","author":"Hu","year":"2015","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.sopen.2023.10.008_bb0060","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1093\/annonc\/mdy201","article-title":"nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial","volume":"29","author":"Yardley","year":"2018","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.sopen.2023.10.008_bb0065","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s10549-019-05203-1","article-title":"Vinorelbine plus Capecitabine (Vinocap): a retrospective analysis in heavily pretreated HER2 negative metastatic breast cancer patients","volume":"176","author":"Torres","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"10.1016\/j.sopen.2023.10.008_bb0070","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1007\/s12282-022-01357-x","article-title":"Effectiveness of eribulin as first-line or second-line chemotherapy for HER2-negative hormone-resistant advanced or metastatic breast cancer: findings from the multi-institutional, prospective, observational KBCRN A001: E-SPEC study","volume":"29","author":"Kikawa","year":"2022","journal-title":"Breast Cancer"},{"issue":"7","key":"10.1016\/j.sopen.2023.10.008_bb0075","doi-asserted-by":"crossref","first-page":"6063","DOI":"10.3390\/ijms24076063","article-title":"Epothilones as natural compounds for novel anticancer drugs development","volume":"24","author":"Villegas","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.sopen.2023.10.008_bb0080","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S1470-2045(17)30088-8","article-title":"Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial","volume":"18","author":"Zhang","year":"2017","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.sopen.2023.10.008_bb0085","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.annonc.2020.10.600","article-title":"Efficacy of utidelone plus capecitabine versus capecitabine for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer: final analysis of overall survival in a phase III randomised controlled trial","volume":"32","author":"Xu","year":"2021","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.sopen.2023.10.008_bb0090","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1093\/annonc\/mdy063","article-title":"Randomised phase III trial of vinflunine plus capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with an anthracycline and resistant to taxane","volume":"29","author":"Martin","year":"2018","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.sopen.2023.10.008_bb0095","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.sjbs.2018.01.011","article-title":"Lobaplatin-based regimens outperform cisplatin for metastatic breast cancer after anthracyclines and taxanes treatment","volume":"25","author":"Wang","year":"2018","journal-title":"Saudi J Biol Sci"},{"issue":"2","key":"10.1016\/j.sopen.2023.10.008_bb0100","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.sopen.2023.10.008_bb0105","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s10549-017-4592-y","article-title":"Trastuzumab combined with doublet or single-agent chemotherapy as first-line therapy for HER2-positive metastatic breast cancer","volume":"168","author":"Yu","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.sopen.2023.10.008_bb0110","article-title":"Phase I trial of ipatasertib plus carboplatin, carboplatin\/paclitaxel, or capecitabine and atezolizumab in metastatic triple-negative breast cancer [published online ahead of print, 2023 Apr 6]","volume":"oyad026","author":"Yuan","year":"2023","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.sopen.2023.10.008_bb0115","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1038\/s41467-022-31704-7","article-title":"A randomized phase 3 trial of gemcitabine or nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer","volume":"13","author":"Wang","year":"2022","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.sopen.2023.10.008_bb0120","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.annonc.2020.10.475","article-title":"Assessment of structural chromosomal instability phenotypes as biomarkers of carboplatin response in triple negative breast cancer: the TNT trial","volume":"32","author":"Sipos","year":"2021","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.sopen.2023.10.008_bb0125","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1158\/1078-0432.CCR-15-2137","article-title":"Phase I study of veliparib (ABT-888) combined with cisplatin and vinorelbine in advanced triple-negative breast cancer and\/or BRCA mutation-associated breast cancer","volume":"22","author":"Rodler","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.sopen.2023.10.008_bb0130","first-page":"788","article-title":"Efficacy and toxicity of vinorelbine (NVB)-based regimens in patients with metastatic triple negative breast cancer (mTNBC) pretreated with anthracyclines and taxanes","volume":"37","author":"Du","year":"2015","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"10.1016\/j.sopen.2023.10.008_bb0135","doi-asserted-by":"crossref","first-page":"4657","DOI":"10.12659\/MSM.905300","article-title":"Efficacy and safety of vinorelbine plus cisplatin vs. gemcitabine plus cisplatin for treatment of metastatic triple-negative breast cancer after failure with anthracyclines and taxanes","volume":"23","author":"Wang","year":"2017","journal-title":"Med Sci Monit"},{"issue":"43","key":"10.1016\/j.sopen.2023.10.008_bb0140","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000001928","article-title":"Vinorelbine plus platinum in patients with metastatic triple negative breast cancer and prior anthracycline and Taxane treatment","volume":"94","author":"Li","year":"2015","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.sopen.2023.10.008_bb0145","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13045-016-0297-7","article-title":"Phase II trial of utidelone as monotherapy or in combination with capecitabine in heavily pretreated metastatic breast cancer patients","volume":"9","author":"Zhang","year":"2016","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.sopen.2023.10.008_bb0150","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s10549-023-06894-3","article-title":"Pegylated liposomal doxorubicin (Duomeisu\u00ae) monotherapy in patients with HER2-negative metastatic breast cancer heavily pretreated with anthracycline and taxanes: a single-arm, phase II study","volume":"199","author":"Jiang","year":"2023","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.sopen.2023.10.008_bb0155","doi-asserted-by":"crossref","first-page":"1076469","DOI":"10.3389\/fonc.2023.1076469","article-title":"Efficacy of apatinib 250 mg combined with chemotherapy in patients with pretreated advanced breast cancer in a real-world setting","volume":"13","author":"Zhang","year":"2023","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.sopen.2023.10.008_bb0160","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.clbc.2016.07.005","article-title":"Ramucirumab with Eribulin versus eribulin in locally recurrent or metastatic breast cancer previously treated with anthracycline and taxane therapy: a multicenter, randomized, phase II study","volume":"16","author":"Yardley","year":"2016","journal-title":"Clin Breast Cancer"},{"issue":"10","key":"10.1016\/j.sopen.2023.10.008_bb0165","first-page":"5647","article-title":"Vinorelbine plus gemcitabine or cisplatin as first-line treatment of HER2-negative advanced breast cancer","volume":"37","author":"He","year":"2017","journal-title":"Anticancer Res"}],"container-title":["Surgery Open Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589845023000921?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589845023000921?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T23:22:58Z","timestamp":1762903378000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589845023000921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":33,"alternative-id":["S2589845023000921"],"URL":"https:\/\/doi.org\/10.1016\/j.sopen.2023.10.008","relation":{},"ISSN":["2589-8450"],"issn-type":[{"value":"2589-8450","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of utidelone plus capecitabine in advanced first-line therapy for metastatic breast cancer: A multicenter real-world study","name":"articletitle","label":"Article Title"},{"value":"Surgery Open Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.sopen.2023.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}